New hope for Hard-to-Treat pancreatic cancer: targeted combo trial launches
NCT ID NCT06770452
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a new drug combination for people with advanced pancreatic cancer that has a specific mutation called KRAS G12D. The treatment combines HRS-4642 (a drug that targets the mutated protein), nimotuzumab (an antibody that blocks a growth signal), and standard chemotherapy. The study aims to see how well this combo shrinks tumors and controls the disease in 32 patients who have not had prior treatment for advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-4642 (a KRAS G12D inhibitor) combined with nimotuzumab (an EGFR-targeting antibody) and chemotherapy (gemcitabine + nab-paclitaxel)
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced pancreatic cancer that has a specific KRAS G12D mutation.
What could go wrong
This is a small, early-phase (Phase 2) single-arm study with no comparison group, so results may not be definitive. The combination may cause significant side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••